BioLight Life Sciences (BioLight Life Sciences) EBIT : $-7.16 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences EBIT?

BioLight Life Sciences's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was $-5.62 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.16 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioLight Life Sciences's annualized ROC % for the quarter that ended in Dec. 2023 was -19.25%. BioLight Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -112.07%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioLight Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.67%.

BioLight Life Sciences EBIT Historical Data

The historical data trend for BioLight Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences EBIT Chart

BioLight Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-3.75

-3.66

-0.49

-2.25

-7.16

BioLight Life Sciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															0.95	-1.31	-0.94	-1.54	-5.62

Competitive Comparison of BioLight Life Sciences's EBIT

For the Biotechnology subindustry, BioLight Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLight Life Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioLight Life Sciences's EV-to-EBIT falls into.

BioLight Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-7.16 Mil.

BioLight Life Sciences (NAS:BOLT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioLight Life Sciences's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-2.49 * ( 1 - 0% )	/	( (18.955	+	6.917)	/ 2 )
=	-2.49	/	12.936
=	-19.25 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	24.444	-	0	-	( 5.489	-	max(0, 0	-	24.444	+	5.489	))
=	18.955

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.739	-	0.061	-	( 2.258	-	max(0, 0.605	-	2.366	+	2.258	))
=	6.917

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

BioLight Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.246	/	( ( (0 + max(18.955, 0))	+	(1.115 + max(-0.473, 0)) )	/	2 )
=	-11.246	/	( ( 18.955	+	1.115 )	/	2 )
=	-11.246	/	10.035
=	-112.07 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.146	+	0	+	18.809)	-	(0	+	0	+	0)
=	18.955

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.108	+	0	+	0)	-	(0.061	+	0	+	0.52)
=	-0.473

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioLight Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-7.161	/	267.911
	=	-2.67 %

BioLight Life Sciences EBIT Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLight Life Sciences (BioLight Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

BOLT:Israel

Address

Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101

Website

http://www.bio-light.co.il

BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.